We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In Teva Pharmaceutical Industries Ltd. v. AstraZeneca Pharmaceuticals LP, No. 11-1091 (Fed. Cir. Dec. 1, 2011), the Federal Circuit affirmed the district court’s grant of SJ of invalidity of certain claims of Teva Pharmaceutical Industries Ltd.’s (“Teva”) U.S. Patent No. RE39,502 (“the ’502 patent”) based on AstraZeneca Pharmaceuticals LP’s (“AstraZeneca”) prior invention under 35 U.S.C. 102(g)(2
